Erschienen in:
01.02.2014 | Special Article
From the Journal archives: Understanding the mechanism(s) regulating hypoxic pulmonary vasoconstriction: how an early study has led to novel translational approaches
verfasst von:
Neil M. Goldenberg, MD, PhD, Gregory M. T. Hare, MD, PhD
Erschienen in:
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
|
Ausgabe 2/2014
Einloggen, um Zugang zu erhalten
Summary
Hypoxic pulmonary vasoconstriction (HPV) is a fundamental physiological process whereby ventilation/perfusion matching is optimized through the constriction of the pulmonary circulation supplying poorly ventilated lung units. In their 1981 paper in the Journal, Noble, Kay, and Fisher used a series of animal experiments to show that alveolar carbon dioxide (CO2) plays a critical role in the regulation of hypoxic pulmonary vasoconstriction. At physiological concentrations, CO2 potentiates the HPV response, and the absence of alveolar CO2 blunts HPV. The enhancement of HPV by CO2 resulted in reduced perfusion of specific hypoxic lung regions, thereby improving systemic oxygenation in lung-ventilated dogs.
Authors
William H. Noble, J. Colin Kay, Joseph A. Fisher
Citation
Can Anaesth Soc J 1981; 28: 422-30.
Purpose
To determine the dominant effect of variations in alveolar carbon dioxide tension on hypoxic pulmonary vasoconstriction.
Principal findings
The group found that 1) increasing alveolar carbon dioxide concentrations enhanced hypoxic pulmonary vasoconstriction; 2) this enhancement improved oxygenation in ventilated dogs with regional alveolar hypoxia; and 3) this enhanced oxygenation was not due to increased cardiac output.
Conclusions
Increased alveolar carbon dioxide enhances hypoxic pulmonary vasoconstriction. In clinical scenarios where hypoventilated or hypoxic lung regions exist, e.g., one-lung ventilation or lung consolidation, permissive hypercapnea may improve oxygenation.